{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:11:35Z","timestamp":1793369495244,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Two-dose universal varicella vaccination (UVV) was included in Israel\u2019s national immunization program in 2008. We aimed to evaluate the impact of the UVV program on varicella incidence and healthcare costs in Israel.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective observational study was conducted using the Maccabi Healthcare Services database between 2003 and 2020. Varicella incidence and varicella-related healthcare costs were assessed in the pre- (2003\u20132007) and post-UVV (2010\u20132020) periods. We used time-series analyses with seasonal autoregressive integrated moving average models to estimate the impact of UVV on varicella incidence and regression models with gamma distributions and log-link functions to assess the impact on healthcare costs. Analyses were conducted for the overall population and vaccine-targeted (1\u20137 years) and nontargeted (&lt;1 and &gt;7 years) populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Annual incidence rates per 100,000 declined from 5709.6 (pre-UVV) to 1062.9 (post-UVV) in the vaccine-targeted population and from 1269.8 to 409.6 in the overall population. Time-series analysis suggested 81.8% (95% prediction interval [PI], 67.5\u201387.4) and 67.1% (95% PI, 48.2\u201375.9) reductions in the vaccine-targeted vaccination and overall populations, respectively. The largest estimated reduction in varicella incidence was in children 1 to 2 years of age [91.2% (95% PI, 53.4\u201395.3)]. Mean direct medical costs decreased between pre- and post-UVV periods by 82% (95% confidence interval, 77\u201386) in the vaccine-targeted group and 51% (95% confidence interval, 44\u201358) overall.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This real-world study demonstrates the substantial reduction in the disease and economic burden of varicella in the vaccine-targeted and overall population following the introduction of a 2-dose UVV program in Israel.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004787","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:44:40Z","timestamp":1742402680000},"page":"593-598","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Universal Varicella Vaccination in Israel: A Time-series Analysis, 2003 to 2020"],"prefix":"10.1097","volume":"44","author":[{"given":"Noga","family":"Fallach","sequence":"first","affiliation":[{"name":"Kahn-Sagol-Maccabi Research and Innovation Institute, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieralessandro","family":"Lasalvia","sequence":"additional","affiliation":[{"name":"NeuroEconomix, Bogota, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjiri","family":"Pawaskar","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[{"name":"Kahn-Sagol-Maccabi Research and Innovation Institute, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Ben Gurion University of the Negev, Beer-Sheva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7915-8553","authenticated-orcid":false,"given":"Stephanie A.","family":"Kujawski","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection.","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-108-2-221","article-title":"NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention.","volume":"108","author":"Straus","year":"1988","journal-title":"Ann Intern Med"},{"key":"R3-20250805","first-page":"750","article-title":"Age-specific incidence of chickenpox.","volume":"109","author":"Finger","year":"1994","journal-title":"Public Health Rep"},{"key":"R4-20250805","year":"2021"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine.","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","article-title":"Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study.","volume":"131","author":"Baxter","year":"2013","journal-title":"Pediatrics"},{"key":"R7-20250805","first-page":"CD004407","article-title":"Vaccines for measles, mumps, rubella, and varicella in children.","volume":"11","author":"Di Pietrantonj","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 4","key":"R8-20250805","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1093\/infdis\/jiac299","article-title":"The effectiveness of varicella vaccine: 25 years of postlicensure experience in the United States.","volume":"226","author":"Shapiro","year":"2022","journal-title":"J Infect Dis"},{"key":"R9-20250805","first-page":"265","article-title":"Varicella and herpes zoster vaccines: WHO position paper, June 2014.","volume":"89","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"R10-20250805","year":"2020"},{"key":"R11-20250805","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s15010-006-6604-4","article-title":"Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines.","volume":"34","author":"Cohen","year":"2006","journal-title":"Infection"},{"key":"R12-20250805"},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1111\/apa.13320","article-title":"Immunisation led to a major reduction in paediatric patients hospitalised because of the varicella infection in Israel.","volume":"105","author":"Elbaz","year":"2016","journal-title":"Acta Paediatr"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.4161\/hv.23943","article-title":"Secular trends of chickenpox among military population in Israel in relation to introduction of varicella zoster vaccine 1979\u20132010.","volume":"9","author":"Mimouni","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R15-20250805"},{"key":"R16-20250805"},{"key":"R17-20250805","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1016\/j.vaccine.2022.07.012","article-title":"The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: a national database analysis, 2008-2019.","volume":"40","author":"Pawaskar","year":"2022","journal-title":"Vaccine"},{"key":"R18-20250805","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/vaccines10071151","article-title":"Trends in varicella burden of disease following introduction of routine childhood varicella vaccination in Argentina: a 12-year time series analysis.","volume":"10","author":"Giglio","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R19-20250805"},{"key":"R20-20250805","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","article-title":"Global impact of varicella vaccination programs.","volume":"15","author":"Varela","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R21-20250805","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14760584.2020.1825947","article-title":"Varicella vaccination in Italy and Germany - different routes to success: a systematic review.","volume":"19","author":"Kauffmann","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"R22-20250805","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1093\/infdis\/jiac221","article-title":"Monitoring varicella vaccine impact on varicella incidence in the United States: surveillance challenges and changing epidemiology, 1995-2019.","volume":"226","author":"Marin","year":"2022","journal-title":"J Infect Dis"},{"key":"R23-20250805","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1186\/s12889-023-17098-1","article-title":"Trends in age-specific varicella incidences following the introduction of the general recommendation for varicella immunization in Germany, 2006-2022.","volume":"23","author":"Moek","year":"2023","journal-title":"BMC Public Health"},{"key":"R24-20250805","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jpeds.2016.02.040","article-title":"Strong additional effect of a second varicella vaccine dose in children in Germany, 2009-2014.","volume":"173","author":"Siedler","year":"2016","journal-title":"J Pediatr"},{"key":"R25-20250805","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4161\/hv.34311","article-title":"Impact of universal vaccination against varicella in Italy.","volume":"11","author":"Bechini","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R26-20250805","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.vaccine.2024.02.002","article-title":"Effectiveness of the combined MMRV Priorix-Tetra vaccine against varicella in a large Italian region: a case-control study.","volume":"42","author":"Fortunato","year":"2024","journal-title":"Vaccine"},{"key":"R27-20250805","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1093\/cid\/ciaa1704","article-title":"The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mitigation strategies on seasonal respiratory viruses: a tale of 2 large metropolitan centers in the United States.","volume":"72","author":"Sherman","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:05:43Z","timestamp":1754427943000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004787","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}